GILD · GILEAD SCIENCES, INC.

💊 Upcoming FDA Decisions

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Oct 2). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area and cash runway. Not investment advice. See the full PDUFA calendar →

📣 What GILD Says Is Next

• in 2026 · “With up to four potential launches and five Phase 3 updates anticipated in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results”
  Company press release, May 7, 2026 · SEC filing
• in 2026 · “Excluding the impact of acquired in-process research and development expenses, Gilead expects the transaction to be modestly dilutive to earnings per share in 2026 and 2027, and accretive in 2028 and thereafter, subject to FDA approval of anito-cel.”
  Company press release, Apr 28, 2026 · SEC filing
• in 2028 · “Upon FDA approval of anito-cel, the proposed transaction is expected to be accretive to earnings per share in 2028 and thereafter.”
  Company press release, Feb 23, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Nov 2026 · Phase 1 · Recruiting · Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Par
  Registry primary completion date, not a results date
• Nov 2026 · Phase 1 · Active Trial · Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
  Registry primary completion date, not a results date
• Dec 2026 · Phase 1 · Recruiting · Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and
  Registry primary completion date, not a results date
• Dec 2026 · Phase 1 · Active Trial · Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
  Registry primary completion date, not a results date
• Dec 2026 · Phase 3 · Active Trial · Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC
  Registry primary completion date, not a results date
• Dec 2026 · Phase 2 · Active Trial · Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not GILD's own candidates): Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate, Capecitabine, Flucytosine, Fluorouracil, Leucovorin, Nivolumab, Oxaliplatin, Pembrolizumab, Abemaciclib, Pioglitazone, Atezolizumab, Avelumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GILD holds $3.2B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 15 · Low

• No operating cash burn in latest filings
• FDA decision in 81 days +15

Recent financing filings on SEC EDGAR:

• Aug 6, 2026 · Shelf registration · S-3ASR

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GILD files for a raise →

👥 Who Owns GILD

Share count 1,239,955,155 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.